Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 651 to 700 of 2486 results for term

  1. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  2. Breast reconstruction using lipomodelling after breast cancer treatment (HTG280)

    Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment. This involves taking fat from the abdomen or thighs and injecting it into the breast in the area of the deformity caused by surgery.

  3. Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)

    Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.

  4. Oral health promotion: general dental practice (NG30)

    This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.

  5. Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)

    Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.

  6. Fractures (non-complex): assessment and management (NG38)

    This guideline covers assessing and managing non-complex fractures that can be treated in the emergency department or orthopaedic clinic. It aims to improve practice so that people with fractures receive the care that they need without unnecessary tests and treatments.

  7. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  8. EDI roadmap and annual action plan

    NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.

  9. Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica (HTG425)

    Evidence-based recommendations on epiduroscopic lumbar discectomy through the sacral hiatus for sciatica in adults. This involves removing the part of the spinal disc pressing against the spinal nerve, to relieve pain.

  10. Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee (HTG340)

    Evidence-based recommendations on arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee. This involves using a radiofrequency probe to heat and smooth any defects and rough edges in the cartilage.

  11. Endoscopic submucosal dissection of gastric lesions (HTG233)

    Evidence-based recommendations on endoscopic submucosal dissection (ESD) of gastric lesions. This involves inserting a thin telescope through the mouth into the stomach to view the area and removing the lesion with special equipment.

  12. Percutaneous tibial nerve stimulation for faecal incontinence (HTG263)

    Evidence-based recommendations on percutaneous tibial nerve stimulation (PTNS) for faecal incontinence. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current through the needle to the nerves that control bowel function.

  13. Epithelial radiofrequency ablation for Barrett's oesophagus (HTG219)

    Evidence-based recommendations on epithelial radiofrequency ablation for Barrett's oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy cells.

  14. Pancreatic cancer in adults: diagnosis and management (NG85)

    This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

  15. Intravascular lithotripsy for calcified arteries in peripheral arterial disease (HTG707)

    Evidence-based recommendations on intravascular lithotripsy for calcified arteries in peripheral arterial disease. This involves using pressure waves to soften arterial plaque and widen the artery to improve blood flow.

  16. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    doses, or at higher doses taken short term. - There is not much evidence about taking aspirin at higher doses long term in...

  17. Occipital nerve stimulation for intractable chronic migraine (HTG310)

    Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.

  18. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  19. Key question: safe

    This resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.

  20. Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (TA1046)

    Evidence-based recommendations on zolbetuximab (Vyloy) with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma in adults.

  21. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5...

  22. Physical health of people in prisons (QS156)

    This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

  23. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

  24. Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer (TA100)

    Evidence-based recommendations on capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer in adults.

  25. Transition between inpatient mental health settings and community or care home settings (NG53)

    This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

  26. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  27. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG770)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias. This involves implanting a cardiac pacemaker that does not have leads directly into the internal wall of the heart.

  28. Diabetes: admission rates (ketoacidosis) (IND46)

    This indicator covers admission rates due to diabetic ketoacidosis in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG64

  29. High-intensity focused ultrasound for glaucoma (HTG527)

    Evidence-based recommendations on high-intensity focused ultrasound for glaucoma in adults. This involves using high-intensity ultrasound to destroy a small amount of the tissue that makes fluid in the eye.

  30. Endovascular stent-grafting of popliteal aneurysms (HTG259)

    Evidence-based recommendations on endovascular stent-grafting of popliteal aneurysms. This involves inserting a ‘stent-graft’ device through the femoral artery (in the groin) lining the inside of the aneurysm.

  31. Dupilumab for treating moderate to severe atopic dermatitis (TA534)

    Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.

  32. Psoriasis (QS40)

    This quality standard covers assessing and managing psoriasis in adults, young people and children. It describes high-quality care in priority areas for improvement.

  33. Haematological cancers (QS150)

    This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (children, adults and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

  34. Depression and anxiety: recovery post-IAPT (IND37)

    This indicator covers the proportion of people treated by Improving Access to Psychological Therapies (IAPT) for anxiety disorders who return to full function. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG54

  35. Diabetes: admission rates (renal replacement therapy) (IND45)

    This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63

  36. Rheumatoid arthritis: register (IND107)

    This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55

  37. Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

    Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion.

  38. Caesarean birth (QS32)

    This quality standard covers the care of pregnant women or pregnant people who are considering having or may need to have a caesarean birth, including those who have had a caesarean birth in the past. It includes decision making, reducing the risk of complications and care after a caesarean birth. It describes high-quality care in priority areas for improvement.

  39. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

  40. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

  41. Safeguarding adults in care homes (NG189)

    This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.

  42. Diabetes: asking about erectile dysfunction (IND105)

    This indicator covers the percentage of male patients with diabetes with a record of being asked about erectile dysfunction in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM51

  43. Aortic valve reconstruction with processed bovine pericardium (HTG461)

    Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium. This involves replacing a damaged aortic valve with a new valve made from chemically treated cow pericardium.

  44. Non-surgical reduction of the myocardial septum (HTG18)

    Evidence-based recommendations on non-surgical reduction of myocardial septum. This involves inserting a catheter into the femoral artery and passing it up into the heart under X-ray control.